High-risk prostate cancer: A disease of genomic instability

被引:26
|
作者
Tapia-Laliena, Maria A. [1 ]
Korzeniewski, Nina [1 ]
Hohenfellner, Markus [1 ]
Duensing, Stefan [1 ]
机构
[1] Heidelberg Univ, Sch Med, Dept Urol, Heidelberg, Germany
关键词
Prostate cancer; Genomic instability; Somatic mutations; DNA damage; Translational therapeutics; Biomarkers; IN-SITU HYBRIDIZATION; DNA-REPAIR; CHROMOSOME INSTABILITY; GENETIC INSTABILITY; ERG; FUSION; REARRANGEMENT; MUTATIONS; DELETIONS; CHROMOTHRIPSIS;
D O I
10.1016/j.urolonc.2014.02.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: In this review, we will discuss the latest advances in our understanding of the relationship between the cellular DNA damage response and genomic instability in prostate cancer and the emerging possibilities to exploit these aberrations as prognostic biomarkers and guides for personalized patient management. Methods: Important findings related to genomic instability in prostate cancer were retrieved from the literature and combined with our own results and a translational perspective. Results: Prostate cancer is characterized by a highly altered genomic landscape with a wide spectrum of genomic alterations, including somatic mutations, copy number alterations (CNAs), gene fusions, complex chromosomal rearrangements, and aneuploidy. In addition, massive DNA damaging events, including chromothripsis and chromoplexy, which can lead to extensive genomic insults in a single step, have been identified. A number of these genomic aberrations have been found to provide prognostic information and can therefore help to identify high-risk patients. In addition, defects in the DNA damage checkpoint and repair machinery can potentially be harnessed for therapeutic purposes. Conclusions: Genomic instability plays a crucial role in the malignant progression of prostate cancer and can be exploited for the development of novel prognostic biomarkers and innovative therapies. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1101 / 1107
页数:7
相关论文
共 50 条
  • [21] Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer
    Nordstroem, Tobias
    Van Blarigan, Erin L.
    Ngo, Vy
    Roy, Ritu
    Weinberg, Vivian
    Song, Xiaoling
    Simko, Jeffry
    Carroll, Peter R.
    Chan, June M.
    Paris, Pamela L.
    PROSTATE, 2016, 76 (04): : 339 - 348
  • [22] Genomics and risk stratification in high-risk prostate cancer
    Al Awamlh, Bashir Al Hussein
    Shoag, Jonathan E.
    NATURE REVIEWS UROLOGY, 2019, 16 (11) : 641 - 642
  • [23] Genomics and risk stratification in high-risk prostate cancer
    Bashir Al Hussein Al Awamlh
    Jonathan E. Shoag
    Nature Reviews Urology, 2019, 16 : 641 - 642
  • [24] PET/CT in High-Risk Prostate Cancer
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (06) : 30N - 30N
  • [25] Results of surgery for high-risk prostate cancer
    Joniau, Steven
    Tosco, Lorenzo
    Briganti, Alberto
    Vanden Broeck, Thomas
    Gontero, Paolo
    Karnes, R. Jeffrey
    Spahn, Martin
    Van Poppel, Hein
    CURRENT OPINION IN UROLOGY, 2013, 23 (04) : 342 - 348
  • [26] Surgery for high-risk localized prostate cancer
    Schmitges, Jan
    Trinh, Quoc-Dien
    Walz, Jochen
    Graefen, Markus
    THERAPEUTIC ADVANCES IN UROLOGY, 2011, 3 (04) : 173 - 182
  • [27] HDR brachytherapy for high-risk prostate cancer
    Lo, TCM
    Bouyounes, BT
    Goodman, N
    Bihrle, W
    Roth, RA
    CANCER JOURNAL, 2001, 7 (06): : 527 - 527
  • [28] Radical prostatectomy for high-risk prostate cancer
    Ofer Yossepowitch
    James A. Eastham
    World Journal of Urology, 2008, 26 : 219 - 224
  • [29] Multimodal approaches to high-risk prostate cancer
    Koupparis, A.
    Gleave, M. E.
    CURRENT ONCOLOGY, 2010, 17 : S33 - S37
  • [30] Chemotherapy for localized, high-risk prostate cancer
    Narayan, S
    Smith, DC
    Sandler, HM
    SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (02) : 152 - 157